Antibe Therapeutics Closes C$35 Million Public Offering for Growth

Antibe Therapeutics is making a big move to fuel its growth. The company has closed a C$35 million public offering, giving it the financial boost it needs to take its business to the next level.

This significant investment will allow Antibe to accelerate its plans and pursue new opportunities. With a strong financial foundation, the company can focus on developing its products and expanding its reach.

The public offering is a major milestone for Antibe, marking a significant step forward in its journey. By securing this funding, the company is well-positioned for future success.

For more insights, see: Central Illinois Public Service Company

Sun Pharmaceutical Industries, an Indian company, has entered into an agreement to acquire a 100% stake in Antibe Therapeutics.

The acquisition is part of Sun Pharma's strategy to expand its pharmaceutical and healthcare portfolio, particularly in the area of pain and inflammation management.

Antibe Therapeutics is a clinical-stage biotechnology company based in Ontario, Canada, specializing in developing novel drugs focused on reducing pain and inflammation.

You might like: Sun Alliance (company)

The transaction is subject to a "reverse vesting order" and approval from the Ontario Superior Court of Justice (Commercial List).

The acquisition is expected to be closed before March 7, 2025.

Antibe Therapeutics is currently under court-observed liquidation proceedings and is managed by a court-appointed receiver.

Sun Pharma has entered into a definitive agreement with the receiver to acquire Antibe via a reverse vesting order.

The transaction involves transferring certain excluded assets and liabilities to a residual company from Antibe prior to closing.

The decision to acquire 100% stake follows Sun Pharma subsidiary Taro Pharmaceuticals entering into an agreement with Antibe.

The acquisition consideration will not be disclosed until the closing of the transaction, as indicated by the court-appointed receiver.

On a similar theme: Internation Transaction Bank with Code Swift

Antibe Therapeutics has made a major announcement. The company has agreed to a bought deal public offering of units for gross proceeds of C$35 million.

This financing will provide Antibe with the necessary funds to advance its pipeline of nonsteroidal anti-inflammatory drug (NSAID) products.

The units will be priced at C$1.10 per unit and consist of one common share and one-half of one warrant.

Worth a look: One Swiss Bank

Antibe Therapeutics is a Canadian pharmaceutical company that specializes in developing novel analgesics for treating pain.

The company's lead product, otenzapril, is a non-opioid pain reliever that targets the COX-2 enzyme, which is involved in pain and inflammation.

Antibe Therapeutics is focused on addressing the opioid crisis by providing effective and safer pain management options.

Antibe Therapeutics is a company that's developing innovative pain relief products. Their lead drug, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen, a commonly used non-steroidal anti-inflammatory drug (NSAID).

Otenaproxesul is being developed as a safer non-opiod analgesic for acute pain, targeting the post-operative pain market and potentially broader applications like migraines, dysmenorrhea, and dental pain.

Unlike standard naproxen, Otenaproxesul does not induce damage to the gastrointestinal tract. This is a significant improvement over traditional pain relief options.

In May 2014, Antibe completed pre-clinical studies on Otenaproxesul, followed by the first human dosing for Phase I of its human clinical trials later that year.

Broaden your view: Meyer Brothers Drug Company

However, clinical trials were suspended in January 2015 due to safety concerns, only to be restarted in March 2015.

Antibe's hard work paid off with successful results from the Phase 2B gastrointestinal safety study for Otenaproxesul in March 2018.

The company's second drug, an opioid-replacement for post-surgical pain, is expected to start clinical trials in late 2023.

Antibe Therapeutics is a Canadian biopharmaceutical company.

Their mission is to create and commercialize innovative therapeutics that address unmet medical needs.

Antibe was founded in 2010, and its headquarters are located in Toronto, Canada.

The company is focused on developing a new class of non-addictive pain therapeutics.

Antibe's lead product candidate, ATB-346, is a potent inhibitor of COX-2 enzymes, which play a key role in pain and inflammation.